Skip to main content

Table 1 Key features of the two community based case studies

From: When they see us, it’s like they have seen the benefits!”: experiences of study benefits negotiations in community-based studies on the Kenyan Coast

Feature

The RSV-study

The Malaria-study

Study question/objective

Define and quantify who acquires infection from whom in relation to transmission of respiratory syncytial virus (RSV) in households.

Evaluate the efficacy of a ‘promising’ malaria candidate vaccine against malaria disease in infants and children, and across diverse malaria transmission settings in Africa; aimed to address key safety and efficacy information required for vaccine licensure.

Study design

Basic science descriptive study.

Double blind (observer blind), randomized, controlled, multi-centre study.

Study period

Oct 2009 – June 2010; participant involvement for 6 months.

2008 – 2013 (later extended to 2015); participant involvement for 34 months.

Number of study sites

One site in KEMRI-WT, Kilifi.

Eleven sites in seven African countries.

Study area in Kilifi

One location, 15 kms from the Kilifi County Hospital (KCH), within KHDSS.

Three administrative divisions, 30 kms from KCH, 5 locations, in Kilifi County.

Composition of study team

A total of 16 team members;

Minimum of 47 staff;

• 10 FWs, 2 data entry clerks, one each SFW, clinician, coordinator, PI and senior researcher,

• 36 FWs, 3 SFWs, 3 clinicians, 2 Medical officers, and one each of study coordinator, PI and senior researcher;

• Team also included shared staff (lab technicians, drivers) with other projects.

• Team also included shared staff (data entry clerks, lab technicians, and drivers) with other projects.

Participants

Entire household in a defined geographic locality; household - where members living in the same compound and with a common eating arrangement e.g. share meals made from the same kitchen. HH selected if had an infant born after previous RSV epidemic; and at least one elder sibling.

Children aged 6-12 weeks and 5-17 months at first vaccination; 16,000 children across the 11 sites, a minimum of 6,000 in each of the age category;

For Kilifi site, allocated total of 900 children, 600 and 300 in the 5-17 months 6-12 weeks group respectively.